Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 19, 2010

View Archived Issues

Anvyl claims new allosteric modulators of nicotinic acetylcholine receptor alpha7

New antimalarial agents presented by 4SC

Czech scientists disclose new cell division protein kinase inhibitors

RaQualia discovers new CB2 receptor agonists

Roche identifies new inhibitors of GlyT-1

Crystal Biopharmaceutical describes new HDAC inhibitors

Abbott begins ABT-267 trial in healthy volunteers and patients with hepatitis C

Xenon Pharma begins phase II XEN-402 trial in postherpetic neuralgia

GSK describes mechanism of new antibacterial agent GSK-299423

Urocortin-2 has long-term beneficial effects in model of myocardial infarction

Add-on vandetanib to docetaxel improves progression-free survival in NSCLC

Combination of three transcription factors reprograms fibroblasts into cardiomyocytes

FDA grants NX-001 orphan drug status for prevention of delayed kidney graft function

Biogen Idec and Knopp Neurosciences collaborate on dexpramipexole for ALS

Repros seeks meeting with FDA to discuss phase III Androxal protocol

Intellect Neurosciences locks database for phase Ib OX-1 trial

FDA grants Urigen Pharmaceuticals type C meeting for URG-101

CSL Behring receives FDA approval to extend shelf life of Hizentra

Quark Pharma and Novartis enter into licensing option agreement for QPI-1002

Shire withdraws NDA for ProAmatine

BioMarin acquires ZyStor Therapeutics and its lead product ZC-701

Chugai provides update on R&D developments

Clavis begins enrollment in phase III trial of elacytarabine in late-stage AML

FDA grants priority review to ipilimumab in previously treated advanced melanoma

FDA grants orphan status to lorvotuzumab mertansine for small cell lung cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...